CA2412882A1 - Polypeptides glycosyles a extension peptidique - Google Patents
Polypeptides glycosyles a extension peptidique Download PDFInfo
- Publication number
- CA2412882A1 CA2412882A1 CA002412882A CA2412882A CA2412882A1 CA 2412882 A1 CA2412882 A1 CA 2412882A1 CA 002412882 A CA002412882 A CA 002412882A CA 2412882 A CA2412882 A CA 2412882A CA 2412882 A1 CA2412882 A1 CA 2412882A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- amino acid
- peptide
- thr
- asn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01001—Alpha-amylase (3.2.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01015—Polygalacturonase (3.2.1.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y602/00—Ligases forming carbon-sulfur bonds (6.2)
- C12Y602/01—Acid-Thiol Ligases (6.2.1)
- C12Y602/01003—Long-chain-fatty-acid-CoA ligase (6.2.1.3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
L'invention concerne des polypeptides glycosyl~s comprenant la structure primaire NH2-X-Pp-COOH dans laquelle X est une addition peptidique contenant un site de glycosylation ou contribuant ~ ce dernier, et Pp est un polypeptide d'int~rÚt. La structure primaire peut Útre Nh2-Px-X-Py-COOH dans laquelle Px est une partie N-terminale d'un polypeptide Pp d'int~rÚt, Py est une partie C-terminale dudit polypeptide Pp, et X est une addition peptidique contenant un site de glycosylation ou contribuant ~ ce dernier. Les polypeptides glycosyl~s possdent des propri~t~s am~lior~es par rapport au polypeptide d'int~rÚt.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200001027 | 2000-06-30 | ||
DKPA200001027 | 2000-06-30 | ||
DKPA200001092 | 2000-07-14 | ||
DKPA200001092 | 2000-07-14 | ||
PCT/DK2000/000743 WO2001049830A2 (fr) | 1999-12-30 | 2000-12-29 | Enzymes lysosomales ameliorees et activateurs d"enzymes lysosomales |
DKPCT/DK00/00743 | 2000-12-29 | ||
DKPCT/DK01/00090 | 2001-02-09 | ||
PCT/DK2001/000090 WO2001058493A1 (fr) | 2000-02-11 | 2001-02-09 | Conjugates of follicle stimulating hormones |
PCT/DK2001/000459 WO2002002597A2 (fr) | 2000-06-30 | 2001-06-29 | Polypeptides glycosyles a extension peptidique |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2412882A1 true CA2412882A1 (fr) | 2002-01-10 |
Family
ID=56290160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002412882A Abandoned CA2412882A1 (fr) | 2000-06-30 | 2001-06-29 | Polypeptides glycosyles a extension peptidique |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1299535A2 (fr) |
JP (1) | JP2004504016A (fr) |
AU (1) | AU2001267337A1 (fr) |
CA (1) | CA2412882A1 (fr) |
WO (1) | WO2002002597A2 (fr) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
ES2564688T3 (es) | 2001-10-10 | 2016-03-28 | Ratiopharm Gmbh | Remodelación y glicoconjugación de poli(éter) a eritropoyetina |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7226903B2 (en) | 2001-10-10 | 2007-06-05 | Neose Technologies, Inc. | Interferon beta: remodeling and glycoconjugation of interferon beta |
US7439043B2 (en) | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7297511B2 (en) | 2001-10-10 | 2007-11-20 | Neose Technologies, Inc. | Interferon alpha: remodeling and glycoconjugation of interferon alpha |
US7179617B2 (en) | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
US7399613B2 (en) | 2001-10-10 | 2008-07-15 | Neose Technologies, Inc. | Sialic acid nucleotide sugars |
US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7125843B2 (en) | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
US7265085B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7473680B2 (en) | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
US7776581B2 (en) | 2002-06-17 | 2010-08-17 | Chr. Hansen A/S | Method of producing an aspartic protease in a recombinant host organism |
US7553930B2 (en) | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
BRPI0408358A (pt) | 2003-03-14 | 2006-03-21 | Neose Technologies Inc | polìmeros hidrossolúveis ramificados e seus conjugados |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
WO2006127896A2 (fr) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Facteur ix glycopegyle |
US7691603B2 (en) | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
EP2338333B1 (fr) | 2003-04-09 | 2017-09-06 | ratiopharm GmbH | Méthode de glycopegylation et proteines/peptides produits au moyen de ces méthodes |
ES2380093T3 (es) | 2003-05-09 | 2012-05-08 | Biogenerix Ag | Composiciones y métodos para la preparación de mutantes de glucosilación de la hormona del crecimiento humana |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
JP4719686B2 (ja) | 2003-11-24 | 2011-07-06 | バイオジェネリックス アーゲー | GlycoPEG化エリスロポエチン |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
AU2005206796B2 (en) | 2004-01-08 | 2011-06-16 | Ratiopharm Gmbh | O-linked glycosylation of peptides |
CA2560590C (fr) * | 2004-03-25 | 2015-06-16 | Iogen Bio-Products Corporation | Xylanases modifiees a expression amelioree |
MXPA06012676A (es) | 2004-05-04 | 2007-04-02 | Novo Nordisk Healthcare Ag | Glucoformas o-enlazadas de polipeptidos y metodos de fabricacion de los mismos. |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
EP1799249A2 (fr) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Interferon alpha glycopegyle |
JP5948627B2 (ja) | 2004-10-29 | 2016-07-20 | レイショファーム ゲーエムベーハー | 線維芽細胞成長因子(fgf)のリモデリングと糖質ペグ化 |
EP2514757A3 (fr) | 2005-01-10 | 2014-03-05 | ratiopharm GmbH | Facteur de stimulation de colonies de granulocytes glycopegylé |
EP1841787A2 (fr) | 2005-01-25 | 2007-10-10 | Cell Therapeutics, Inc. | Conjugues de proteine biologiquement actives possedant une demi-vie in vivo modifiee |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
EP1888098A2 (fr) | 2005-05-25 | 2008-02-20 | Neose Technologies, Inc. | Formulations d'erythropoietine glycopegylees |
EP1746161A1 (fr) * | 2005-07-20 | 2007-01-24 | Cytheris | IL-7 glycosylée, préparation et utilisations |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
WO2007056191A2 (fr) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Purification de sucre de nucleotide en utilisant des membranes |
WO2007111496A1 (fr) * | 2006-03-28 | 2007-10-04 | Universiteit Utrecht Holding B.V. | Domaines de reconnaissance d'hydrates de carbone améliorés |
WO2008011633A2 (fr) | 2006-07-21 | 2008-01-24 | Neose Technologies, Inc. | Glycosylation de peptides par l'intermédiaire de séquences de glycosylation à liaison o |
US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
PE20081250A1 (es) * | 2006-11-28 | 2008-10-07 | Centelion | FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA |
KR20100016160A (ko) | 2007-04-03 | 2010-02-12 | 바이오제너릭스 에이지 | 글리코페길화 g―csf를 이용하는 치료 방법 |
JP5876649B2 (ja) | 2007-06-12 | 2016-03-02 | ラツィオファルム ゲーエムベーハーratiopharm GmbH | ヌクレオチド糖の改良製造法 |
DK2173890T3 (da) | 2007-06-21 | 2011-06-27 | Univ Muenchen Tech | Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
JP5769142B2 (ja) * | 2007-09-04 | 2015-08-26 | 独立行政法人酒類総合研究所 | ピヒア属酵母において異種タンパク質を高分泌させる方法 |
WO2009108806A1 (fr) | 2008-02-27 | 2009-09-03 | Novo Nordisk A/S | Molécules de facteur viii conjuguées |
JP2010183885A (ja) * | 2009-02-13 | 2010-08-26 | Kobe Univ | タンパク質の製造方法およびそれに用いる発現ベクター |
CN105477641B (zh) | 2010-05-21 | 2021-03-23 | Xl-蛋白有限责任公司 | 生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途 |
CN105296447A (zh) * | 2010-11-08 | 2016-02-03 | 阿米库斯治疗学公司 | 具有增强的稳定性和增强的保留催化活性的变体重组β-葡萄糖脑苷脂酶蛋白 |
US20160296632A1 (en) * | 2013-11-13 | 2016-10-13 | Aequus Biopharma, Inc. | Engineered glycoproteins and uses thereof |
WO2015091130A1 (fr) * | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Procédé pour l'amélioration de la production recombinante de polypeptides de fusion solubles |
US10370692B2 (en) | 2013-12-20 | 2019-08-06 | Hoffmann-La Roche Inc. | Recombinant polypeptide production methods |
PL3313879T3 (pl) | 2015-06-24 | 2022-04-11 | F. Hoffmann-La Roche Ag | Przeciwciała przeciwko receptorowi transferyny z dostosowanym powinowactwem |
MX2018003822A (es) | 2015-10-02 | 2018-06-22 | Hoffmann La Roche | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso. |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
MA47436A (fr) * | 2017-01-31 | 2019-12-11 | Regenxbio Inc | Traitement de la mucopolysaccharidose i avec une alpha-l-iduronidase glycosylée entièrement humaine (idua) |
US11890329B2 (en) | 2017-07-06 | 2024-02-06 | The Trustees Of The University Of Pennsylvania | AAV9-mediated gene therapy for treating mucopolysaccharidosis type I |
SG11202002457RA (en) | 2017-09-22 | 2020-04-29 | Univ Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5218092A (en) * | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
JP2893481B2 (ja) * | 1988-12-23 | 1999-05-24 | ジェンザイム コーポレイション | 酵素的に活性な組換えグルコセレブロシダーゼ |
ZA987497B (en) * | 1997-09-08 | 1999-02-23 | Akzo Nobel Nv | Expression of gonadotropins in dictyostelium |
ATE458007T1 (de) * | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
-
2001
- 2001-06-29 JP JP2002507849A patent/JP2004504016A/ja active Pending
- 2001-06-29 AU AU2001267337A patent/AU2001267337A1/en not_active Abandoned
- 2001-06-29 EP EP01944987A patent/EP1299535A2/fr not_active Withdrawn
- 2001-06-29 WO PCT/DK2001/000459 patent/WO2002002597A2/fr not_active Application Discontinuation
- 2001-06-29 CA CA002412882A patent/CA2412882A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002002597A2 (fr) | 2002-01-10 |
JP2004504016A (ja) | 2004-02-12 |
WO2002002597A3 (fr) | 2002-06-27 |
AU2001267337A1 (en) | 2002-01-14 |
EP1299535A2 (fr) | 2003-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2412882A1 (fr) | Polypeptides glycosyles a extension peptidique | |
US20060160177A1 (en) | Peptide extended glycosylated polypeptides | |
US20200330587A1 (en) | Epstein-barr virus vaccines | |
US11479605B2 (en) | Homodimeric protein constructs | |
US20210284698A1 (en) | Stabilized soluble pre-fusion rsv f polypeptides | |
EP3180020B1 (fr) | Variants d'il-2 modifiés qui activent sélectivement les cellules t régulatrices pour le traitement de maladies auto-immunes | |
US11759514B2 (en) | Stabilized pre-fusion RSV F proteins | |
US20020198162A1 (en) | Antigen library immunization | |
US20190016760A1 (en) | Multimerization of Recombinant Protein by Fusion to a Sequence from Lamprey | |
WO2004044006A1 (fr) | Conjugues de l'interleukine-10 et de polymeres | |
TW201438743A (zh) | 糖鏈加成連接基、含有糖鏈加成連接基與生理活性物質的化合物或其鹽,以及其製造方法 | |
CN111514286B (zh) | 一种寨卡病毒e蛋白结合疫苗及其制备方法 | |
CN114173809A (zh) | 免疫刺激组合物及其用途 | |
WO2013177440A2 (fr) | Réseau de flagelline ordonné utilisé comme immunostimulant | |
Ebrahimi et al. | Fusion and sequence analysis of the influenza A (H9N2) virus M2e and C-terminal fragment of Mycobacterium tuberculosis HSP70 (H37Rv). | |
WO2023282771A1 (fr) | Composition de vaccin contre le coronavirus | |
CN115368468A (zh) | 一种新型冠状病毒SARS-CoV-2突变体疫苗与应用 | |
JPWO2005090576A1 (ja) | 百日咳感染症予防用dna構築物 | |
MXPA00007892A (en) | Antigen library immunization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |